Cue Biopharma
@CueBiopharma
Followers
581
Following
11
Media
445
Statuses
496
Developing a novel class of therapeutic biologics to selectively engage and modulate disease-relevant T cells for the treatment of autoimmune disease and cancer
Boston, Massachusetts
Joined December 2017
We’re pleased to announce the initiation of an investigator sponsored trial of our drug candidate targeting Wilms’ Tumor 1 expressing cancers, with the first patient dosed for recurrent glioblastoma multiforme (rGBM) @DanaFarber Cancer Institute. For more:
0
0
1
Today, we reported second quarter 2025 financial results and recent business highlights. Read our press release to learn more:
0
0
1
Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.
766
3K
10K
We’re honored that a publication featuring our Immuno-STAT® platform received Editor’s Pick by the Journal of Virology! Congrats to co-authors Steven Almo, our Co-founder & Chair of Biochemistry @EinsteinMed, and Simon Low, our VP of Biologics Discovery:
0
0
3
Check out this @TargetedOnc article by @jordynsava discussing our recently announced positive mature Phase 1b data with our lead #oncology asset for the treatment of patients with recurrent/metastatic HPV+ head and neck cancer. Access it here:
targetedonc.com
CUE-101 combined with pembrolizumab shows promising results, achieving a 50% response rate in HPV-positive head and neck cancer patients.
0
0
1
We’re pleased to report a new complete response and confirmed 50% overall response rate in the ongoing Phase 1 trial of our most advanced asset, in HPV+ #HeadandNeckCancer. Read the release for key highlights on the significance of this maturing data:
0
0
4
Thank you, Dr. Colevas @StanfordMed for discussing maturing data from our most advanced clinical stage asset in HPV16+ head and neck cancer (HNSCC), at this years’ DAVA 4th Hawaii Global Summit on Thoracic Malignancies.
In Stanford Cancer Center’s Phase 1 study, Dr. Dimitrios Colevas(@StanfordMed) reports CUE-101 + pembrolizumab yields a 50% ORR and 88% 1-yr OS in 1L HPV16+ R/M HNSCC. Encouraging durable responses & manageable safety profile #Immunotherapy #HNSCC #Oncology #DAVALung
0
1
6
We’re pleased to share encouraging new data from our maturing Phase 1 trial of our most advanced clinical stage asset in HPV+ #HeadandNeckCancer presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies. Learn more:
0
1
5
ICYMI: We’re pleased to announce positive FDA feedback reinforcing plans to advance an IND submission for our lead autoimmune candidate CUE-401, a first-in-class bispecific molecule designed to restore immune tolerance in #AutoimmuneDisease. For details:
0
2
6
We're headed to the @Oppenheimer Innovators in I&I Summit in New York, where our CEO, Dan Passeri, will discuss our innovative I&I program, CUE-401, during the Rheumatology Panel and engage with investors and fellow industry peers in #immunology & #inflammation. #OPCOImmunology
1
1
3
We had a great turnout for our panel on innovations fueling growth in immunology & inflammation at #BIO2025. Our CEO, Dan Passeri, joined industry leaders to explore the science & investment driving I&I’s rapid rise. Thanks to @IAmBiotech, our fellow panelists, & all who came by!
0
0
1
Breakthroughs in immunology & inflammation have made I&I one of biotech’s fastest-growing fields. Our interim CDO, Daniel Baker, M.D., will join @IAmBiotech’s #BIO2025 International Convention for a panel on key aspects driving this growth. For details:
1
0
2
We’re pleased to welcome Jill Broadfoot, CFO of @aTyrNews, to our Board of Directors! Jill brings decades of #biotech leadership and strategic expertise that will be key as we advance our #autoimmune and #oncology programs. Read her bio to learn more:
0
0
2
#ICYM the preclinical proof-of-concept data presentation at the @ASGCTherapy 28th Annual Meeting, you can access the poster on our website to learn more about the potential of our Immuno-STAT biologics to control CAR T cell expansion & persistence in vivo:
0
0
1
In addition to a poster at the @ASCO 2025 Annual Meeting, we’re pleased to share an abstract publication of our lead oncology asset in HPV+ #HeadandNeckCancer. Read it here for more on the investigator-sponsored Phase 2 neoadjuvant #ClinicalTrial: #ASCO25
0
1
2
We’re pleased to announce a poster presentation of the investigator-sponsored Phase 2 neoadjuvant #ClinicalTrial for our lead oncology asset in HPV+ #HeadandNeckCancer at the @ASCO 2025 Annual Meeting. Access the abstract here to learn more: #ASCO2025
0
0
2
#ICYM our Virtual Investor Event, watch the webcast replay for expert insights and key updates on our #autoimmune & #oncology programs, including CUE-401, and CUE-501, recently partnered with Boehringer Ingelheim. Watch here:
0
0
0
RT @LifeSciAdvisors: Join @CueBiopharma $CUE for a virtual event on May 15 at 11am ET featuring Drs. DiPaolo and Cope as they discuss Cue's….
0
2
0
Today, we announced our first quarter 2025 financial results and updated business highlights. Read our press release to learn more: $CUE
0
0
0
We look forward to our presentation on May 16 at @PEGSBoston #PEGSummit. Ahmet Vakkasoglu, PhD, Associate Director, Biologics Discovery & Innovation at Cue Biopharma will discuss how our Immuno-STAT platform is empowering novel immunotherapies. For more:
0
0
2
On May 14, Jesusa Capera-Aragones, PhD, from University of Oxford, UK will present research on our Immuno-STAT biologics for cancer immunotherapy at the European Association for Cancer Research (EACR) Conference. Learn more about the program here:
0
0
0